You just read:

PharmAkea Announces Successful Completion of a Phase 1 Trial in Healthy Subjects For Its Novel LOXL2 Inhibitor, PAT-1251

News provided by

PharmAkea, Inc.

Aug 22, 2017, 05:00 ET